Background: Population-based data on the risk of cardiac death among cancer survivors are
needed. This scenario was evaluated in cancer survivors (> 5 years) registered within the …

Breast cancer is the second most commonly diagnosed cancer, being one of the main health
issues that needs to be addressed worldwide. New therapies have led to a remarkable …

Background: Anthracyclines are a class of chemotherapeutic agents that are used to treat
many different cancers, including breast cancer. Although anthracyclines remain an effective …

Trastuzumab, the humanized monoclonal antibody specific for HER2 receptor, is the gold
standard in the treatment of HER2+ breast cancer. Despite its high therapeutic efficacy …

Trastuzumab has an impressive level of efficacy as regards antineoplasticity, however it can
cause serious cardiotoxic side effects manifested by impaired cardiac contractile function …

The vascular endothelium plays a fundamental role in the maintenance of tissue
homeostasis, regulating local blood flow and other physiological processes …

Purpose We conducted a literature-based meta-analysis of the risk of cardiovascular
toxicities associated with MEK inhibitors. Methods Eligible trials included randomized phase …

Background: We performed a systematic review and meta-analysis of the risk of proteinuria
associated with ramucirumab. Methods: Eligible studies included randomized phase II and …

Introduction The aim of this study was to characterize treatment trends and outcomes of
women who have preexisting cardiovascular disease (CVD) prior to the diagnosis of breast …

The prevalence of breast cancer in women is a fundamental problem in public health
worldwide. There is consensual evidence that many chemotherapeutic agents might have …